Buscar
Biodexa Pharmaceuticals PLC
BDRXAñadir a la lista de seguimiento
2.940USD
-0.060-2.00%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
1.33MCap. mercado
16.87P/E TTM
Más Datos de Biodexa Pharmaceuticals PLC Compañía
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Información de Biodexa Pharmaceuticals PLC
Símbolo de cotizaciónBDRX
Nombre de la empresaBiodexa Pharmaceuticals PLC
Fecha de salida a bolsaDec 08, 2014
Director ejecutivoStamp (Stephen A)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalDec 08
Dirección1 Caspian Point
CiudadABINGDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalCF10 4DQ
Teléfono4401235888300
Sitio Webhttps://www.biodexapharma.com/
Símbolo de cotizaciónBDRX
Fecha de salida a bolsaDec 08, 2014
Director ejecutivoStamp (Stephen A)
Ejecutivos de Biodexa Pharmaceuticals PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Biodexa Pharmaceuticals PLC?
Los cinco principales accionistas de Biodexa Pharmaceuticals PLC son: Dr. Simon Turton
¿Cuántas instituciones poseen acciones de Biodexa Pharmaceuticals PLC (BDRX)?
A fecha de 2026Q1, 26 instituciones poseen acciones de Biodexa Pharmaceuticals PLC, con un valor de mercado combinado de aproximadamente 66.51K, lo que representa el 7.79% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 60313.00.